تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
1.08 US$
−0.03 US$ · -2.70%
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. Another pipeline candidate, IMM-529, is in clinical development with a focus on treating recurrent Clostridium difficile infections. Immuron maintains strategic collaborations, including a research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections. Additionally, it has a collaboration with the Walter Reed Army Institute of Research aimed at creating an oral therapeutic for shigellosis. Established in 1994, Immuron Limited is headquartered in Carlton, Australia.
عند الإغلاق
1.08 US$
−0.03 US$ · -2.70%
بعد ساعات التداول
1.08 US$
0.00 US$ · 0.00%
9 أكتوبر، 4:00 م ET
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. Another pipeline candidate, IMM-529, is in clinical development with a focus on treating recurrent Clostridium difficile infections. Immuron maintains strategic collaborations, including a research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections. Additionally, it has a collaboration with the Walter Reed Army Institute of Research aimed at creating an oral therapeutic for shigellosis. Established in 1994, Immuron Limited is headquartered in Carlton, Australia.
نطاق اليوم
السعر الحالي 1.08 US$
نطاق 52 أسبوعًا
السعر الحالي 1.08 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
72
أقل من القيمة
المشاعر
53
مختلط
المخاطر
66
مخاطر مرتفعة
الزخم
47
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. Another pipeline candidate, IMM-529, is in clinical development with a focus on treating recurrent Clostridium difficile infections. Immuron maintains strategic collaborations, including a research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections. Additionally, it has a collaboration with the Walter Reed Army Institute of Research aimed at creating an oral therapeutic for shigellosis. Established in 1994, Immuron Limited is headquartered in Carlton, Australia.
نطاق اليوم
السعر الحالي 1.08 US$
نطاق 52 أسبوعًا
السعر الحالي 1.08 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (AUD) | السنة المالية 2026 | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 |
|---|---|---|---|---|---|
| الإيرادات | 7.55 مليون AUD | 7.29 مليون AUD | 4.9 مليون AUD | 1.8 مليون AUD | 765.19 ألف AUD |
| تكلفة البضاعة المباعة | 2.68 مليون AUD | 2.52 مليون AUD | 1.57 مليون AUD | 64.63 ألف AUD | 241.69 ألف AUD |
| الربح الإجمالي | 4.87 مليون AUD | 4.77 مليون AUD | 3.34 مليون AUD | 1.74 مليون AUD | 523.5 ألف AUD |
| البحث والتطوير | — | 3.6 مليون AUD | 5.38 مليون AUD | 2.59 مليون AUD | 657.72 ألف AUD |
| مصاريف البيع والمصاريف العمومية والإدارية | 7.61 مليون AUD | 7.94 مليون AUD | 6.59 مليون AUD | 5.15 مليون AUD | 3.94 مليون AUD |
| نفقات التشغيل | 9.5 مليون AUD | 10.11 مليون AUD | 9.14 مليون AUD | 5.31 مليون AUD | 3.39 مليون AUD |
| دخل الفوائد | — | 135.87 ألف AUD | 327.76 ألف AUD | 116.32 ألف AUD | 21.79 ألف AUD |
| مصاريف الفوائد | 14.39 ألف AUD | 7.31 ألف AUD | 7.58 ألف AUD | 9.65 ألف AUD | 6.18 ألف AUD |
| الاستهلاك والإطفاء | — | 49.69 ألف AUD | 44.16 ألف AUD | 48.66 ألف AUD | 26.61 ألف AUD |
| الدخل التشغيلي | −4.63 مليون AUD | −5.34 مليون AUD | −5.8 مليون AUD | −3.57 مليون AUD | −2.87 مليون AUD |
| صافي الدخل | −3.75 مليون AUD | −5.22 مليون AUD | −6.94 مليون AUD | −3.79 مليون AUD | −2.85 مليون AUD |
تم تحديث حقائق الشركة 10 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
المحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
